Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07199309 · ClinicalTrials.gov registry record · Phase 2
A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
A Phase 2 study of Hypertriglyceridemia, sponsored by Marea Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07199309 is a Phase 2 study of Hypertriglyceridemia that is actively recruiting participants, run by Marea Therapeutics. The registered enrollment target is 30 participants, below the 175-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07199309, a Phase 2 study of Hypertriglyceridemia, is actively recruiting participants, sponsored by Marea Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the study is to determine the effect of MAR001 as compared to placebo on levels of the triglycerides (TG) in the postprandial state in adults with elevated TG.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MAR001
Study Locations (1)
California
- Marea Site 301 - Chula Vista
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-26 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07199309
The ClinicalTrials.gov registry entry for NCT07199309 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 175-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (83% lower). The listed sponsor is Marea Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07199309 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07199309 about?
NCT07199309 is a clinical study titled "A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol". The primary objective of the study is to determine the effect of MAR001 as compared to placebo on levels of the triglycerides (TG) in the postprandial state in adults with elevated TG.
What is the current status of trial NCT07199309?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-09-26. Estimated completion is 2026-11.
What conditions does trial NCT07199309 study?
This clinical trial studies the following conditions: Hypertriglyceridemia.
What interventions are being tested in trial NCT07199309?
The interventions under investigation include: Placebo (DRUG), MAR001 (DRUG).
Who is sponsoring clinical trial NCT07199309?
This trial is sponsored by Marea Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07199309 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
ACTIVE NOT RECRUITING · Phase 2
-
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 2
-
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
COMPLETED · Phase 2
-
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
COMPLETED · Phase 2
-
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
RECRUITING · Phase 3
-
Differential Thrombogenesis by EPA and DHA Mediated by HDL
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.